Insider · CIK 0001868719
Mark Plavsic
Files at AURA (Aura Biosciences, Inc.). First filing Oct 16, 2024, latest Feb 17, 2026.
In brief
Mark Plavsic files SEC Form 4 as officer at AURA (Aura Biosciences, Inc.). Since Oct 16, 2024, Mark Plavsic has reported 0 open-market buys worth $0 and 4 open-market sells worth $247k, the latest filed on Feb 17, 2026.
A track record needs three past buys with six months of prices behind them; Mark Plavsic has 0, so none is measured yet.
The newest scored trade: sold $80k of AURA on Feb 17, 2026, filed Feb 17, 2026, scored 39 (weak). In the last 12 months: 0 buys worth $0 and 2 sells worth $158k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
AURA: Aura Biosciences, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 39Weak | Aura Biosciences, Inc. | $80k 15,890 shares | -8% | +7% from low-31% from high | |
| 38Weak | Aura Biosciences, Inc. | $77k 12,169 shares | -6% | +26% from low-47% from high | |
| 30Weak | Aura Biosciences, Inc. | $17k 2,151 shares | -1% | - | |
| 38Weak | Aura Biosciences, Inc. | $73k 7,383 shares | -6% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Feb 17, 2026 | AURA Aura Biosciences, Inc. | 15,890 0.03% of outstanding | $80k | Feb 17, 2026 | none |
| Oct 16, 2025 | AURA Aura Biosciences, Inc. | 12,169 0.02% of outstanding | $77k | Oct 16, 2025 | none |
| Feb 18, 2025 | AURA Aura Biosciences, Inc. | 2,151 0.00% of outstanding | $17k | Feb 18, 2025 | none |
| Oct 16, 2024 | AURA Aura Biosciences, Inc. | 7,383 0.01% of outstanding | $73k | Oct 16, 2024 | none |
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | AURA Aura Biosciences, Inc. | AGrant or award Common Stock | +62,339 | $0.00 | $0 | 243,736 | Mar 3, 2026 |
| Mar 2, 2026 | AURA Aura Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +112,661 | $0.00 | $0 | 112,661 | Mar 3, 2026 |
| Feb 17, 2026 | AURA Aura Biosciences, Inc. | SOpen-market sale Common Stock | -15,890 | $5.05 | $80k | 181,397 | Feb 17, 2026 |
| Oct 16, 2025 | AURA Aura Biosciences, Inc. | SOpen-market sale Common Stock | -12,169 | $6.35 | $77k | 197,287 | Oct 16, 2025 |
| Feb 18, 2025 | AURA Aura Biosciences, Inc. | SOpen-market sale Common Stock | -2,151 | $7.75 | $17k | 209,456 | Feb 18, 2025 |
| Feb 3, 2025 | AURA Aura Biosciences, Inc. | AGrant or award Common Stock | +90,475 | $0.00 | $0 | 211,607 | Feb 4, 2025 |
| Feb 3, 2025 | AURA Aura Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +59,525 | $0.00 | $0 | 59,525 | Feb 4, 2025 |
| Oct 16, 2024 | AURA Aura Biosciences, Inc. | SOpen-market sale Common Stock | -7,383 | $9.85 | $73k | 121,132 | Oct 16, 2024 |
Questions about Mark Plavsic
Answered from the filings on this page, as of the latest one.
Is Mark Plavsic buying or selling?
In the last 12 months Mark Plavsic reported 0 open-market buys worth $0 and 2 open-market sells worth $158k on SEC Form 4; the latest was sold $80k of AURA on Feb 17, 2026. Grants, option exercises and tax withholding are not counted.
How did Mark Plavsic's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mark Plavsic has 0.
Where does Mark Plavsic file Form 4?
Mark Plavsic has filed Form 4 at AURA (Aura Biosciences, Inc.) as Chief Technology Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.